| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.8 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | 0.0093 | 0.8 |
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.8 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0076 | 0.8 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | NSC23766 | CTRPv2 | pan-cancer | AAC | -0.007 | 0.8 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.0068 | 0.8 |
| mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | -0.0061 | 0.8 |